Functional link between adenosine and insulin: A hypothesis for fetoplacental vascular endothelial dysfunction in gestational diabetes

Current Vascular Pharmacology

Volumn 9, Issue 6, 2011, Pages 750-762

  Guzmán Gutiérrez, Enrique ^a   Abarzúa, Fernando ^a   Belmar, Cristian ^a   Nien, Jyh K ^b   Ramírez, Marco A ^a,c   Arroyo, Pablo ^a   Salomón, Carlos ^a   Westermeier, Francisco ^a   Puebla, Carlos ^a   Leiva, Andrea ^a   Casanello, Paola ^a   Sobrevia, Luis ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Section of Gastroenterology   (Chile)

^c UNIVERSIDAD DE ANTOFAGASTA   (Chile)

Author keywords

Adenosine; Endothelium; Fetus; Gestational diabetes; Insulin receptor; Placenta

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR; CAFFEINE; CVT3619; INSULIN; INSULIN RECEPTOR; MEMBRANE RECEPTOR; METFORMIN; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; UNCLASSIFIED DRUG;

ARTICLE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FETUS; FETUS DISEASE; HUMAN; INSULIN SENSITIVITY; METABOLISM; MITOGENESIS; PREGNANCY DIABETES MELLITUS; VASCULAR DISEASE;

ADENOSINE; ANIMALS; DIABETES, GESTATIONAL; ENDOTHELIUM, VASCULAR; FEMALE; FETAL DISEASES; HUMANS; HYPERINSULINISM; INSULIN; PLACENTAL CIRCULATION; PREGNANCY; RECEPTOR, INSULIN;

EID: 80054067527     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111797484062     Document Type: Article

References (124)

1. Desoye G, Hauguel-de Mouzon S. The human placenta in gestational diabetes mellitus. The insulin and cytokine network. Diabetes Care 2007; 30: S120-S126.
2. Barrett HL, Morris J, McElduff A. Watchful waiting: a management protocol for maternal glycaemia in the peripartum period. Aust NZ J Obstet Gynaecol 2009; 49: 162-167.
3. American Diabetes Association Gestational Diabetes Mellitus. Position Statement. Diab Care 2004; 27: S88-S90.
4. Position statement. Diagnosis and classification of diabetes mellitus. American Diabetes Association. Diab Care 2011; 34: S62-S69.
5. Catalano PM, Hauguel-De Mouzon S. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am J Obstet Gynecol 2011; 204: 479-487.
6. Nold JL, Georgieff MK. Infants of diabetic mothers. Pediatr Clin North Am 2004; 51: 619-637.
7. Myatt L. Reactive oxygen and nitrogen species and functional adaptation of the placenta. Placenta 2010; 31: S66-S69.
8. Westermeier F, Salomón C, González M, et al. Insulin restores gestational diabetes mellitus-reduced adenosine transport involving differential expression of insulin receptor isoforms in human umbilical vein endothelium. Diabetes 2011; 60:1677-1687.
9. Burnstock G. Vessel tone and remodeling. Nat Med 2006; 12: 16-17.
10. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology 2009; 111: 904-915.
11. Westermeier F, Puebla C, Vega JL, et al. Equilibrative nucleoside transporters in fetal endothelial dysfunction in diabetes mellitus and hyperglycaemia. Curr Vasc Pharmacol 2009; 7: 435-449.
12. Sobrevia L, Abarzúa F, Nien JK, et al. Differential placental macrovascular and microvascular endothelial dysfunction in gestational diabetes. Placenta 2011; 25: S159-S164.
13. Westgate JA, Lindsay RS, Beattie J, et al. Hyperinsulinemia in cord blood in mothers with type 2 diabetes and gestational diabetes mellitus in New Zealand. Diabetes Care 2006; 29: 1345-1350.
14. Lindsay RS, Westgate JA, Beattie J, et al. Inverse changes in fetal insulin-like growth factor (IGF)-1 and IGF binding protein-1 in association with higher birth weight in maternal diabetes. Clin Endocrinol 2007; 66: 322-328.
15. Colomiere M, Permezel M, Riley C, Desoye G, Lappas M. Defective insulin signaling in placenta from pregnancies complicated by gestational diabetes mellitus. Eur J Endocrinol 2009; 160: 567-578.
16. Maguire MH, Szabó I, Valkó IE, Finley BE, Bennett TL. Simultaneous measurement of adenosine and hypoxanthine in human umbilical cord plasma using reversed-phase high-performance liquid chromatography with photodiode-array detection and on-line validation of peak purity. J Chromatogr B Biomed Sci Appl 1998; 707: 33-41.
17. Muñoz G, San Martín R, Farías M, Cea L, Casanello P, Sobrevia L. Insulin restores glucose-inhibition of adenosine transport by increasing the expression and activity of the equilibrative nucleoside transporter 2 in human umbilical vein endothelium. J Cell Physiol 2006; 209: 826-835.
18. Srinivasan M, Herrero P, McGill JB, et al. The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2005; 46: 42-48.
19. Ardiansyah, Shirakawa H, Sugita Y, Koseki T, Komai M. Antimetabolic syndrome effects of adenosine ingestion in stroke-prone spontaneously hypertensive rats fed a high-fat diet. Br J Nutr 2010; 104: 48-55.
20. Tchirikov M, Rybakowski C, Hüneke B, Schoder V, Schröder HJ. Umbilical vein blood volume flow rate and umbilical artery pulsatility as 'venous-arterial index' in the prediction of neonatal compromise. Ultrasound Obstet Gynecol 2002; 20: 580-585.
21. Marzioni D, Tamagnone L, Capparuccia L, et al. Restricted innervation of uterus and placenta during pregnancy: evidence for a role of the repelling signal Semaphorin 3A. Dev Dyn 2004; 231: 839-848.
22. Reviriego J, Alonso MJ, Ibañez C, Marín J. Action of adenosine and characterization of adenosine receptors in human placental vasculature. Gen Pharmacol 1990; 21: 227-233.
23. Vásquez G, Sanhueza F, Vásquez R, et al. Role of adenosine transport in gestational diabetes-induced L-arginine transport and nitric oxide synthesis in human umbilical vein endothelium. J Physiol 2004; 560: 111-122.
24. San Martín R, Sobrevia L. Gestational diabetes and the adenosine/ L-arginine/nitric oxide (ALANO) pathway in human umbilical vein endothelium. Placenta 2006; 27: 1-10.
25. Fredholm BB, Ijzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology LXXXI. Nomenclature and classification of adenosine receptors: an update. Pharmacol Rev 2011; 63: 1-34.
26. Wyatt AW, Steinert JR, Wheeler-Jones CPD, et al. Early activation of the p42/p44 MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium insensitive mechanism. FASEB J 2002; 16: 1584-1594.
27. Escudero C, Casanello P, Sobrevia L. Human equilibrative nucleoside transporters 1 and 2 may be differentially modulated by A2B adenosine receptors in placenta microvascular endothelial cells from pre-eclampsia. Placenta 2008; 29: 816-825.
28. Ray CJ, Marshall JM. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J Physiol 2006; 570: 85-96.
29. Pandolfi A, Di Pietro N. High glucose, nitric oxide, and adenosine: a vicious circle in chronic hyperglycemia? Cardiovasc Res 2010; 86: 9-11.
30. Lappas M, Hiden U, Froehlich J, Desoye G, Haugel-de Mouzon S, Jawerbaum A. The role of oxidative stress in the pathophysiology of gestational diabetes mellitus. Antioxid Redox Signal 2011; doi:10.1089/ars.2010.3765.
31. Sobrevia L, Nadal A, Yudilevich DL, Mann GE. Activation of Larginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol 1996; 1; 490: 775-781.
32. Farías M, San Martín R, Puebla C, et al. Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol 2006; 208: 451-460.
33. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
34. Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos 2010; 38: 833-840.
35. Brown MA, North L, Hargood J. Uteroplacental Doppler ultrasound in routine antenatal care. Aust N Z J Obstet Gynaecol 1990; 30: 303-307.
36. Biri A, Onan A, Devrim E, Babacan F, Kavutcu M, Durak I. Oxidant status in maternal and cord plasma and placental tissue in gestational diabetes. Placenta 2006; 27: 327-332.
37. Pietryga M, Brazert J, Wender-Ozegowska E, Dubiel M, Gudmundsson S. Placental Doppler velocimetry in gestational diabetes mellitus. J Perinat Med 2006; 34: 108-110.
38. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735-743.
39. Vega JL, Puebla C, Vásquez R, et al. TGF-ß1 inhibits expression and activity of hENT1 in a nitric oxide-dependent manner in human umbilical vein endothelium. Cardiovasc Res 2009; 82: 458-467.
40. von Mandach U, Lauth D, Huch R. Maternal and fetal nitric oxide production in normal and abnormal pregnancy. J Matern Fetal Neonatal Med 2003; 13: 22-27.
41. Hiden U, Lang I, Ghaffari-Tabrizi N, Gauster M, Lang U, Desoye G. Insulin action on the human placental endothelium in normal and diabetic pregnancy. Curr Vasc Pharmacol 2009; 7: 460-466.
42. González M, Gallardo V, Rodríguez N, et al. Insulin-stimulated Larginine transport requires SLC7A1 gene expression and is associated with human umbilical vein relaxation. J Cell Physiol 2011; doi:10.1002/jcp.22635.
43. Genua M, Pandini G, Cassarino MF, Messina RL, Frasca F. c-Abl and insulin receptor signaling. Vitam Horm 2009; 80: 77-105.
44. Greene MF, Solomon CG. Gestational diabetes mellitus - time to treat. N Engl J Med 2005; 352: 2544-2546.
45. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-634.
46. Sundell J, Knuuti J. Insulin and myocardial blood flow. Cardiovasc Res 2003; 57: 312-319.
47. Sonne MP, Alibegovic AC, Hojbjerre L, Vaag A, Stallknecht B, Dela F. The effect of ten days of bed rest on metabolic and vascular insulin action. A study in individuals at risk for type 2 diabetes. J Appl Physiol 2010; 108: 830-837.
48. Timmerman KL, Lee JL, Dreyer HC, et al. Insulin stimulates human skeletal muscle protein synthesis via an indirect mechanism involving endothelial-dependent vasodilation and mammalian target of rapamycin complex 1 signaling. J Clin Endocrinol Metab 2010; 95: 3848-3857.
49. Jo M, Krause B, Casanello P, Sobrevia L. Differential reactivity to insulin in human umbilical and chorionic vessels from normal and gestational diabetic pregnancies. J Dev Orig Health Dis 2009; 1: S307 (Abstract).
50. Youngren J. Regulation of insulin receptor function. Cell Mol Life Sci 2007; 64: 873-891.
51. Joost HG, Steinfelder HJ. Modulation of insulin sensitivity by adenosine. Effects on glucose transport, lipid synthesis, and insulin receptors of the adipocyte. Mol Pharmacol 1982; 22: 614-618.
52. Vergauwen L, Hespel P, Richter EA. Adenosine receptors mediate synergistic stimulation of glucose uptake and transport by insulin and by contractions in rat skeletal muscle. J Clin Invest 1994; 93: 974-981.
53. Johansson GS, Arnqvist HJ. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am J Physiol 2006; 291: E1124-E1130.
54. Németh ZH, Bleich D, Csóka B, et al. Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 2007; 21: 2379-2388.
55. 2+ uptake. Cell Biochem Funct 2008; 26: 833-843.
56. Figler RA, Wang G, Srinivasan S, et al. Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 2011; 60: 669-679.
57. Barradas MA, Mikhailidis DP, Dandona P. ADPase activity in human maternal and cord blood: possible evidence for a placentaspecific vascular protective mechanism. Int J Gynaecol Obstet 1990; 31:15-20.
58. Meyer B, Calvert D, Moses R. Free fatty acids and gestational diabetes mellitus. Aust N Z J Obstet Gynaecol 1996; 3: 255-257.
59. Chen X, Scholl TO, Leskiw M, Savaille J, Stein TP. Differences in maternal circulating fatty acid composition and dietary fat intake in women with gestational diabetes mellitus or mild gestational hyperglycemia. Diabetes Care 2010; 33: 2049-2054.
60. Barradas MA, Mikhailidis DP, Dandona P. The effect of nonesterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract 1987; 3: 9-19.
61. Catalano PM, Nizielski SE, Shao J, Preston L, Qiao L, Friedman JE. Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: relationship to FFA during pregnancy. Am J Physiol Endocrinol Metab 2002; 282: E522-E533.
62. Schulte G, Fredholm BB. The Gs-coupled adenosine A2B receptor recruits divergent pathways to regulate ERK1/2 and p38. Exp Cell Res 2003; 290: 168-176.
63. Donoso MV, López R, Miranda R, Briones R, Huidobro-Toro JP. A2B adenosine receptor mediates human chorionic vasoconstriction and signals through arachidonic acid cascade. Am J Physiol 2005; 288: H2439-H2449.
64. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein- mediated signaling and the role of accessory proteins. Cell Signal 2002; 2: 99-108.
65. Löffler M, Morote-Garcia JC, Eltzschig SA, Coe IR, Eltzschig HK. Physiological roles of vascular nucleoside transporters. Arterioscler Thromb Vasc Biol 2007; 27: 1004-1013.
66. Li RW, Yang C, Sit AS, Lin SY, Ho EY, Leung GP. Physiological and pharmacological roles of vascular nucleoside transporters. J Cardiovasc Pharmacol 2011; doi: 10.1097/FJC.0b013e31820eb788.
67. Farías M, Puebla C, Westermeier F, et al. Nitric oxide reduces SLC29A1 promoter activity and adenosine transport involving transcription factor complex hCHOP-C/EBPa in human umbilical vein endothelial cells from gestational diabetes. Cardiovasc Res 2010; 86: 45-54.
68. Salomón C, Westermeier F, Casanello P, Sobrevia L. Differential modulation of insulin receptor isoforms expression and NOS activity by insulin in human placenta microvascular endothelial cells from gestational diabetes. Placenta 2010; 31: A.80 (Abstract).
69. Sobrevia L, González M. A role for insulin on L-arginine transport in fetal endothelial dysfunction in hyperglycaemia. Curr Vasc Pharmacol 2009; 7: 467-474.
70. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
71. Nitert MD, Chisalita SI, Olsson K, Bornfeldt KE, Arnqvist HJ. IGF-I/insulin hybrid receptors in human endothelial cells. Mol Cell Endocrinol 2005; 229: 31-37.
72. Seino S, Seino M, Nishi S, Bell G. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 1989; 86: 114-118.
73. Kristensen C, Wiberg FC, Schäffer L, Andersen AS. Expression and characterization of a 70-kDa fragment of the insulin receptor that binds insulin. Minimizing ligand binding domain of the insulin receptor. J Biol Chem 1998; 273: 17780-17786.
74. Thorsøe KS, Schlein M, Steensgaard DB, Brandt J, Schluckebier G, Naver H. Kinetic evidence for the sequential association of insulin binding sites 1 and 2 to the insulin receptor and the influence of receptor isoform. Biochemistry 2010; 49: 6234-6246.
75. Bergandi L, Silvagno F, Russo I, et al. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 12: 2215-2221.
76. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904.
77. Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocrinol Rev 2007: 28: 463-491.
78. Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313: 756-761.
79. Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signaling. Cell 1985; 40: 747-758.
80. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278-3288.
81. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 2001; 17: 363-373.
82. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30: 586-623.
83. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate- 1. Endocrinology 2003; 144: 2650-2658.
84. Sciacca L, Cassarino MF, Genua M, et al. Insulin analogues differently activate insulin receptor isoforms and post-receptor signaling. Diabetologia 2010; 53: 1743-1753.
85. Sen S, Talukdar I, Liu Y, Tam J, Reddy S, Webster N. Muscleblind- like 1 (mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic Enhancer. J Biol Chem 2010; 285: 25426-25437.
86. Giudice J, Leskow FC, Arndt-Jovin DJ, Jovin TM, Jares-Erijman EA. Differential endocytosis and signaling dynamics of insulin receptor variants IR-A and IR-B. J Cell Sci 2011; 124: 801-811.
87. Moller DE, Yokota A, White MF, Pazianos AG, Flier JS. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J Biol Chem 1989; 265: 14979-149785.
88. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990; 9: 2409-2413.
89. Benecke H, Flier JS, Moller DE. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J Clin Invest 1992; 89: 2066-2070.
90. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 39684-39695.
91. Mosthaf L, Vogt B, Häring HU, Ullrich A. Altered expression of insulin receptor types A and B in the skeletal muscle of noninsulin- dependent diabetes mellitus patients. Proc Natl Acad Sci USA 1991; 88: 4728-4730.
92. Kellerer M, Sesti G, Seffer E, et al. Altered pattern of insulin receptor isotypes in skeletal muscle membranes of type 2 (noninsulin- dependent) diabetic subjects. Diabetologia 1993; 36: 628-632.
93. Sesti G, Tullio AN, D'Alfonso R, et al. Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein. Acta Diabetol 1994; 31: 59-65.
94. Savkur R, Philips V, Cooper H. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29: 40-47.
95. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 7: 412-419.
96. Fredholm BB, Lindström K, Dionisotti S, Ongini E. [3H]SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies. J Neurochem 1998; 70:1210-1216.
97. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci USA 1993; 90: 10365-10369.
98. Klotz KN, Hessling J, Hegler J, et al. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 1-9.
99. Linden J, Thai T, Figler H, Jin X, Robeva AS. Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol 1999; 56: 705-713.
100. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5: 247-264.
101. Kim YC, Ji X, Melman N, Linden J, Jacobson KA. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem 2000; 43: 1165-1172.
102. Daly JW, Padgett WL, Secunda SI, Thompson RD, Olsson RA. Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology 1993; 46: 91-100.
103. Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 7-10.
104. Liang BT, Urso R, Sambraski E, Jacobson KA. Adenosine A3 receptors in muscle protection. In: Borea P, Ed. A3 Adenosine Receptors from Cell Biology to Pharmacology, Springer: Berlin, 2010; pp. 257-280.
105. Jacobson KA, Hoffmann C, Kim YC, et al. Molecular recognition in P2 receptors: ligand development aided by molecular modeling and mutagenesis. Prog Brain Res 1999; 120: 119-132.
106. Abo-Salem OM, Hayallah AM, Bilkei-Gorzo A, Filipek B, Zimmer A, Müller CE. Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther 2004; 308: 358-366.
107. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers Handb Exp Pharmacol 2009; 193: 25-58.
108. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG. Trial Investigators. Metformin vs. insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.
109. Godfrey KM, Robinson S, Hales CN, Barker DJ, Osmond C, Taylor KP. Nutrition in pregnancy and the concentrations of proinsulin, 32-33 split proinsulin, insulin, and C-peptide in cord plasma. Diabet Med 1996; 13: 868-873.
110. Homko C, Sivan E, Chen X, Reece EA, Boden G. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 568-573.
111. Kousta E, Lawrence NJ, Godsland IF, et al. Insulin resistance and beta-cell dysfunction in normoglycaemic European women with a history of gestational diabetes. Clin Endocrinol 2003; 59: 289-297.
112. Joost HG, Steinfelder HJ. Modulation of insulin sensitivity by adenosine. Effects on glucose transport, lipid synthesis, and insulin receptors of the adipocyte. Mol Pharmacol 1982; 22: 614-618.
113. Espinal J, Challiss RA, Newsholme EA. Effect of adenosine deaminase and an adenosine analogue on insulin sensitivity in soleus muscle of the rat. FEBS Lett 1983; 158: 103-106.
114. Green A. Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist. J Biol Chem 1987; 262: 15702-15707.
115. Webster JM, Heseltine L, Taylor R. In vitro effect of adenosine agonist GR79236 on the insulin sensitivity of glucose utilisation in rat soleus and human rectus abdominus muscle. Biochim Biophys Acta 1996; 1316: 109-113.
116. Ciaraldi TP, Morales AJ, Hickman MG, Odom-Ford R, Olefsky JM, Yen SS. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 1421-1425.
117. Laine H, Nuutila P, Luotolahti M, et al. Insulin-induced increment of coronary flow reserve is not abolished by dexamethasone in healthy young men. J Clin Endocrinol Metab 2000; 85: 1868-1873.
118. Laine H, Sundell J, Nuutila P, et al. Insulin induced increase in coronary flow reserve is abolished by dexamethasone in young men with uncomplicated type 1 diabetes. Heart 2004; 90: 270-276.
119. Sundell J, Nuutila P, Laine H, et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes 2002; 51: 1125-1130.
120. Han DH, Hansen PA, Nolte LA, Holloszy JO. Removal of adenosine decreases the responsiveness of muscle glucose transport to insulin and contractions. Diabetes 1998; 47: 1671-1675.
121. Derave W, Hespel P. Role of adenosine in regulating glucose uptake during contractions and hypoxia in rat skeletal muscle. J Physiol 1999; 515: 255-263.
122. Pawelczyk T, Sakowicz-Burkiewicz M, Kocbuch K, Szutowicz A. Differential effect of insulin and elevated glucose level on adenosine handling in rat T lymphocytes. J Cell Biochem 2005; 96: 1296-1310.
123. Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM. Comparison of the antilipolytic effects of an A1 adenosine receptor partial agonist in normal and diabetic rats. Diabetes Obes Metab 2009; 11: 95-101.
124. Kolnes AJ, Ingvaldsen A, Bolling A, et al. Caffeine and theophylline block insulin-stimulated glucose uptake and PKB phosphorylation in rat skeletal muscles. Acta Physiol (Oxf) 2010; 200: 65-74.